Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The business is a recognized leader in managing Covid-19 and mRNA research programs
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
